GLP-1 Receptor Agonists in Autoimmune Hepatitis with Type 2 Diabetes

Safety Profile and Efficacy

• GLP-1 RAs can reduce gallbladder disorders and rare cases of pancreatitis in patients with autoimmune hepatitis and type 2 diabetes, with a need for careful consideration of these risks 1

Hepatoprotective Effects and Cardiovascular Benefits

• The American Heart Association recommends GLP-1 RAs for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, as these agents reduce major adverse cardiovascular events and demonstrate anti-inflammatory effects 2
• GLP-1 RAs reduce hepatic fat and steatosis, decreasing inflammation associated with metabolic liver disease, and provide hepatoprotective effects in chronic liver disease 1

Dosage and Monitoring

• Initiate GLP-1 RAs using standard dosing protocols, starting at low doses and titrating slowly to minimize gastrointestinal side effects, and monitor for liver function tests at baseline and periodically 1
• Monitor for heart rate changes, with an expected increase of 3-10 beats/min 1